117 related articles for article (PubMed ID: 16273135)
1. Pharmacodynamic equivalence study of CFC-free and CFC-containing procaterol hydrochloride metered-dose inhalers.
Kawai M; Nakashima M; Takaori S; Nakamura Y; Akamatsu K; Nakashima M; Miyamoto T
Methods Find Exp Clin Pharmacol; 2005 Oct; 27(8):555-8. PubMed ID: 16273135
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic study of procaterol hydrochloride dry powder inhaler: evaluation of pharmacodynamic equivalence between procaterol hydrochloride dry powder inhaler and procaterol hydrochloride metered-dose inhaler in asthma patients in a randomized, double-dummy, double-blind crossover manner.
Kawai M; Sakai A; Takaori S; Hiura A; Sakata N; Nakashima M; Miyamoto T
Methods Find Exp Clin Pharmacol; 2005; 27(6):385-9. PubMed ID: 16179955
[TBL] [Abstract][Full Text] [Related]
3. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study.
Houghton CM; Langley SJ; Singh SD; Holden J; Monici Preti AP; Acerbi D; Poli G; Woodcock A
Br J Clin Pharmacol; 2004 Oct; 58(4):359-66. PubMed ID: 15373928
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD.
Bhattacharya A; Bhargava S; Singh V; Talwar D; Whig J; Rebello J; Purandare S; Gogtay J
Int J Chron Obstruct Pulmon Dis; 2016; 11():1469-76. PubMed ID: 27418820
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group.
Ayres JG; Millar AB; Sykes AP
Respir Med; 2000 Jun; 94 Suppl B():S42-50. PubMed ID: 10919685
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients.
Langley SJ; Sykes AP; Batty EP; Masterson CM; Woodcock A
Ann Allergy Asthma Immunol; 2002 May; 88(5):488-93. PubMed ID: 12027070
[TBL] [Abstract][Full Text] [Related]
9. Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma.
Ramsdell JW; Colice GL; Ekholm BP; Klinger NM
Ann Allergy Asthma Immunol; 1998 Dec; 81(6):593-9. PubMed ID: 9892032
[TBL] [Abstract][Full Text] [Related]
10. Acute safety of the CFC-free propellant HFA-134a from a pressurized metered dose inhaler.
Donnell D; Harrison LI; Ward S; Klinger NM; Ekholm BP; Cooper KM; Porietis I; McEwen J
Eur J Clin Pharmacol; 1995; 48(6):473-7. PubMed ID: 8582466
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Bioequivalence Between the New Procaterol Hydrochloride Hydrate Dry Powder Inhaler and the Approved Dry Powder Inhaler in Patients With Asthma in a Randomized, Double-Blind, Double-Dummy, Crossover Comparison Study: A Phase 3 Study.
Shirai R; Suzaki Y; Sato K; Takeuchi Y; Tokimatsu I; Koga N; Kadota J; Ohashi K
Clin Pharmacol Drug Dev; 2018 May; 7(4):392-399. PubMed ID: 28884969
[TBL] [Abstract][Full Text] [Related]
12. Equivalence of salbutamol 200 microg four times daily propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. Eastern European study group.
Salat D; Popov D; Sykes AP
Respir Med; 2000 Jun; 94 Suppl B():S22-8. PubMed ID: 10919682
[TBL] [Abstract][Full Text] [Related]
13. Budesonide administered using chlorofluorocarbon and hydrofluoroalkane pressurized metered-dose inhalers: pharmacokinetics, pharmacodynamics and clinical equivalence.
Singh D; Tutuncu A; Lohr I; Carlholm M; Polanowski T
Int J Clin Pharmacol Ther; 2007 Sep; 45(9):485-95. PubMed ID: 17907591
[TBL] [Abstract][Full Text] [Related]
14. Switching from Ventolin CFC to Ventolin HFA is well tolerated and effective in patients with asthma.
Lumry W; Noveck R; Weinstein S; Barnhart F; Vandermeer A; Murray A; Reisner C
Ann Allergy Asthma Immunol; 2001 Mar; 86(3):297-303. PubMed ID: 11289328
[TBL] [Abstract][Full Text] [Related]
15. Efficacy response of inhaled HFA-albuterol delivered via the breath-actuated Autohaler inhalation device is comparable to dose in patients with asthma.
Gross G; Cohen RM; Guy H
J Asthma; 2003; 40(5):487-95. PubMed ID: 14529098
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Albuterol (Salbuterol) Multi-dose Dry-Powder Inhaler and ProAir(®) Hydrofluoroalkane for the Treatment of Persistent Asthma: Results of Two Randomized Double-Blind Studies.
Kerwin EM; Taveras H; Iverson H; Wayne D; Shah T; Lepore MS; Miller DS
Clin Drug Investig; 2016 Jan; 36(1):55-65. PubMed ID: 26541599
[TBL] [Abstract][Full Text] [Related]
17. Safety of long-term treatment with HFA albuterol.
Ramsdell JW; Klinger NM; Ekholm BP; Colice GL
Chest; 1999 Apr; 115(4):945-51. PubMed ID: 10208190
[TBL] [Abstract][Full Text] [Related]
18. Clinical comparability between the CFC and HFA budesonide pressurised metered-dose inhalers in paediatric patients with asthma: a randomised controlled trial.
Escribano A; Tutuncu A; Löhr I; Carlholm M; Polanowski T
Curr Med Res Opin; 2006 Jun; 22(6):1085-92. PubMed ID: 16846541
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects.
Kempsford R; Handel M; Mehta R; De Silva M; Daley-Yates P
Respir Med; 2005 Apr; 99 Suppl A():S11-9. PubMed ID: 15777604
[TBL] [Abstract][Full Text] [Related]
20. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
Dusser D; Vicaut E; Lefrançois G;
Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
